Avelumab and Merkel Cell Carcinoma: A Causation Analysis
From General Health to Specific Exposure
Historically, general health and science communication has emphasized foundational wellness principles—balanced nutrition, routine physical activity, and preventive screenings—as cornerstones of population health. This broad framework has served to educate the public on maintaining physiological resilience and recognizing early warning signs of disease. Within this legacy, discussions of pharmaceutical interventions have typically focused on therapeutic benefits and common adverse effects, framed within a context of overall risk-benefit assessment. As we transition toward a more specialized inquiry, it becomes necessary to narrow the lens from general health maintenance to specific exposure scenarios encountered in clinical and occupational settings. One such scenario involves the administration of Avelumab, a programmed death-ligand 1 (PD-L1) blocking antibody indicated for certain malignancies. In this context, the question of causation arises: does exposure to Avelumab itself contribute to the development of Merkel Cell Carcinoma? This pivot moves the discussion from broad health education to a focused examination of drug exposure and oncogenic risk, particularly relevant for healthcare workers and patients who may have sustained or repeated contact with this therapeutic agent. The shift demands careful consideration of exposure pathways, duration, and potential cumulative effects, without invoking mechanistic disease claims.
Avelumab and Merkel Cell Carcinoma: A Medical and Risk Narrative
The question of whether avelumab causes Merkel cell carcinoma (MCC) requires careful examination of the drug's pharmacology, clinical trial data, and reported adverse effects. Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic MCC, making it the first therapeutic agent specifically approved for this indication (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the JAVELIN Merkel 200 trial, where confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). MCC is a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and incidence rates are increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). Given that avelumab is used to treat MCC, the question of causation is nuanced: does the drug induce de novo MCC, or does it affect the natural history of existing disease?
Mechanistic Pathways and Clinical Evidence
The evidence does not support a direct causal pathway by which avelumab induces MCC. Instead, avelumab's mechanism—blocking PD-L1 to enhance immune response—can lead to immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). For example, a case report described hypercalcaemia secondary to reactivation of sarcoidosis during avelumab treatment for metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, no evidence links avelumab to the initiation of MCC. In fact, immune checkpoint inhibitors (ICIs) like avelumab are associated with durable responses and significant clinical benefit in advanced MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). The drug is used to treat MCC, not cause it.
Timeline, Risk Anchors, and Causation Considerations
The timeline between avelumab exposure and documented harm is relevant only in the context of disease progression or refractoriness. Approximately 50% of patients with advanced MCC treated with ICI progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For avelumab-refractory patients, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). Studies have explored subsequent therapies, such as ipilimumab plus nivolumab, in avelumab-refractory MCC, with some patients responding (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/36450381/). This indicates that progression or lack of response is a known outcome, not a new harm caused by the drug. The adequacy of warnings regarding avelumab and MCC must be assessed in light of the drug's approved indication. Avelumab is specifically approved for metastatic MCC, and its prescribing information includes warnings about immune-related adverse events, such as pneumonitis, colitis, hepatitis, endocrinopathies, and others. However, there is no warning about causing MCC because the drug is used to treat it. The risk for affected patients is primarily related to disease progression or irAEs, not induction of a new malignancy. For patients who progress on avelumab, the risk of inadequate treatment options is a significant concern, as noted in studies of avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/36450381/). From a causation perspective, the Bradford Hill criteria—such as strength of association, consistency, specificity, temporality, biological gradient, plausibility, coherence, experiment, and analogy—do not support a causal relationship between avelumab and MCC. The drug is used to treat MCC, and its approval was based on demonstrated efficacy. The temporal relationship is reversed: avelumab is administered after MCC diagnosis. No evidence suggests that avelumab induces MCC in patients without pre-existing disease. The only plausible link is that avelumab may alter the immune environment, potentially affecting tumor behavior, but this is a therapeutic effect, not causation of a new cancer.
Conclusion
In summary, the evidence does not indicate that avelumab causes Merkel cell carcinoma. Instead, avelumab is a treatment for MCC, with proven efficacy in a subset of patients. The drug's mechanism involves immune activation, which can lead to irAEs but not to de novo MCC. For patients with MCC, the primary risks are disease progression and irAEs, which are adequately addressed in prescribing information. Future research should continue to explore mechanisms of resistance and optimal sequencing of therapies for avelumab-refractory patients.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Does Avelumab cause Merkel cell carcinoma?
No, the evidence does not support that Avelumab causes Merkel cell carcinoma. Avelumab is actually approved to treat metastatic Merkel cell carcinoma. Its mechanism of action involves blocking PD-L1 to enhance the immune response against cancer cells, and it does not induce de novo MCC.
What are the risks associated with Avelumab treatment?
The primary risks of Avelumab are immune-related adverse events (irAEs) such as pneumonitis, colitis, hepatitis, and endocrinopathies, as well as disease progression in some patients. There is no evidence that Avelumab increases the risk of developing new cancers.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.